Avidity Biosciences (RNA) Q1 2025 earnings summary

Executive summary

• Focused on developing Antibody Oligonucleotide Conjugates (AOCs) for rare diseases, with three programs in potentially registrational trials: del-desiran (DM1), del-brax (FSHD), and del-zota (DMD44).

• Achieved positive topline data for del-zota in DMD44, supporting a planned BLA submission by year end 2025 and highlighting consistent efficacy and safety across late-stage trials for DMD44, DM1, and FSHD.

• Completed enrollment for key clinical trials, including EXPLORE44-OLET for del-zota and FORTITUDE biomarker cohort for del-brax, ahead of schedule.

• Building global commercial infrastructure with preparations for a first potential U.S. product launch in 2026.

• No product sales revenue to date; revenue derived from collaboration agreements.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled approximately $1.4 billion as of March 31, 2025, providing a cash runway into mid-2027.

• Collaboration revenue was $1.6 million for Q1 2025, down from $3.5 million in Q1 2024.

• Net loss for Q1 2025 was $115.8 million, compared to $68.9 million in Q1 2024.

• Research and development expenses increased to $99.5 million from $66.8 million year-over-year.

• General and administrative expenses rose to $33.6 million from $13.9 million year-over-year.

Outlook and guidance

• Multiple clinical and regulatory milestones anticipated in 2025, including BLA submission for del-zota and updates from ongoing trials.

• Marketing application submissions for del-desiran planned to begin in 2026 in the U.S., EU, and Japan.

• Cash position supports execution across three late-stage programs and commercial launch preparations.

• No expectation of product sales revenue in the immediate term; continued reliance on external financing and collaborations.